Fulgent Genetics Inc Stock News

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto

Ultra strong balance sheet that has a liquid asset balance almost equivalent to its current market capitalization. Profitable core laboratory testing business even without the temporary COVID-19 windf

Today, we revisit Fulgent Genetics. The company continues to manage through a huge drop off in Covid testing revenues as the pandemic ebbs. However, 'core' testing sales are seeing impressive growth

Investors who avoided losing money this year are positioned to consider stocks that are strong conviction buys. An investment idea earns that level of faith when management demonstrates a consistent h

As the COVID testing frenzy winds down, FLGT is faced with a pleasant problem: what to do with the money it has amassed during the pandemic. Its $880 million dry powder represents a major war chest th

While the large-capitalization firms attract massive institutional support and the small enterprises grab retail eyeballs, the center lane investments – even those labeled the best mid-cap stocks to

Cramer circled back to Fulgent Genetics after an investor asked him about the stock last week.

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2022 Results Conference Call November 7, 2022 4:30 PM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Paul Kim - CFO Brandon Perthuis - Chief Com

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 88.24% and 1.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto

Investors suffered their third unpleasant quarter in a row in the quarter that just ended. After this pounding, quite a few stocks look attractive to me.

This healthcare business has tailwinds behind it.

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2022 Results Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Nicole Borsje - Investor Relations, The Blueshirt Group Ming Hsieh - Chair

Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

These companies have low share prices and high potential.

The company has raked in well over $1B of cash from its epic Covid testing ramp up, apart from a host of contacts and putting the company on the map. It is spending some of that on acquisitions and a